PubMed Health⌕ Search

Biomedical subjects

R A Cash

Publications and source records attributed to R A Cash.

At least 37 records · Page 2Linked to original sources
PubMed1976

Efficacy of a live oral cholera vaccine in human volunteers.

A live attenuated oral cholera vaccine has been given to volunteers with complete safety. The vaccine strain appeared to multiply significantly in intestinal contents and to result in appreciable vibriocidal antibody response. Subsequent challenge with virulent Inaba vibrios demonstrated substantial protection from clinical illness and from vibrio shedding. The possibility of reversion to toxin production is discussed.

Administration, Oral↗
PubMed1975

Enterotoxigenic Escherichia-coli-associated diarrheal disease in Apache children.

A search for intestinal enterotoxigenic Escherichia coli was made in 59 Apache children hospitalized with 64 episodes of acute diarrhea. Esch. coli isolates from acute-phase and convalescent-phase specimens of small-bowel fluid and stool were tested in three currently recognized models: the adult-rabbit ileal loop; infant rabbit; and the adrenal-cell assay. Enterotoxigenic strains were isolated from 10 children during acute diarrheal episodes (16 per cent); none were isolated from convalescent-phase specimens. None of 64 "enteropathogenic" serotypes of Esch. coli from 43 children with diarrhea, however, caused fluid production in the ileal-loop model. These results suggest that enterotoxigenic Esch. coli may be the cause of considerable diarrhea in this population and that the term "enteropathogenic" as applied to serotypes of Esch. coli needs to be redefined.

Acute Disease↗
PubMed1975

Antibodies to heat-labile Escherichia coli enterotoxin in Apaches in Whiteriver, Arizona.

Antitoxin titers to heat-labile Escherichia coli enterotoxin were measured in Apache children hospitalized with acute diarrhea and in Apaches of different age groups without diarrhea in Whiteriver, Ariz. The study suggests that in this locale, exposure to enterotocigenic E. coli is probably widespread and occurs early in life. Antitoxin titer rises after idarrheal disease associated with enterotocigenic E. coli infection, however, were not regulary found.

Antitoxins↗
PubMed1975

Attempted prevention of diarrheal disease in Apache children with a non-absorbable broad-spectrum antimicrobial.

A double-blind study was conducted to test the prophylactic effect of a non-absorbable broad-spectrum antimicrobial (oral colistin sulfate) against acute diarrhea in Apache children. Children 1 to 6 months old had over twice the morbidity from diarrhea if assigned to the antimicrobial group as compared to placebo, while the toddler group (7-30 months) taking the antimicrobial had somewhat less diarrhea. Enteropathogenic E. coli were significantly more often isolated from the antimicrobial group (but only in well children). No special effect on the children's growth by the antimicrobial was discerned.

Age Factors↗
PubMed1974

Live oral cholera vaccine: evaluation of the clinical effectiveness of two strains in humans.

El Tor Ogawa C14-S5 and EW-6, two live vaccine candidate strains, were given to volunteers in varying doses with and without bicarbonate. Vibrios were found in the stool of one of 32 men given the vaccine strain, and only three men developed a significant titer rise (fourfold or greater) at 2 weeks of vibriocidal or antitoxic antibody. Five men who had previously received 10(9) organisms of the C14-S5 strain were challenged subsequently with virulent Ogawa 395 Vibrio cholerae. The rate of clinical infection in these men was no different than in unvaccinated controls. It was demonstrated that the live oral cholera vaccines did not remain viable in the intestine long enough to act antigenically.

Administration, Oral↗
PubMed1971

Clinical studies of the use of bacteriophage in the treatment of cholera.

This study reports the use of bacteriophage prepared in the USSR in the treatment of cholera. Patients with acute cholera were rehydrated with a standard intravenous solution and were then given a bacteriophage preparation in addition to maintenance intravenous therapy. The titre of the phage preparations was between 10(8) and 10(9) pfu/ml. Bacteriophage was given by mouth (25 ml for adults and 20 ml for children) for 3 days; in addition, some patients were also given an intramuscular injection (20 ml) of phage on the first day in hospital. For comparison, other groups of patients were given a standard tetracycline regimen or a placebo preparation. Daily vibrio and phage counts were made on stool samples from all patients and the vibrio strains isolated from each patient were tested for sensitivity to the phage preparation.The criteria used to evaluate the various therapies were duration of diarrhoea, volume of stool, and duration of vibrio excretion.The results of the study demonstrate that, in the doses used, the therapeutic effect of bacteriophage, if any, was markedly inferior to that of tetracycline and that in the current state of our knowledge bacteriophage, as used in this study, has no place in the treatment of cholera.

Adolescent↗